Active	Status	Sponsor type	Region	Phase	Filter
4 Active 8 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Awada, Ahmad
PELICAN, NCT03515798 / 2016-001868-11: Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer	Active, not recruiting	2	52	Europe	Pembrolizumab Injection, MK3475, neoadjuvant EC-paclitaxel chemotherapy, Epirubicine, Cyclophosphamide, Paclitaxel	Institut Paoli-Calmettes, MSD France, Oncodistinct	Inflammatory Breast Cancer	08/22	08/27
FIPO23, NCT06154291: FIH XON7 in Advanced/Metastatic Solid Tumors	Recruiting	1/2	255	Europe	XON7	Xenothera SAS	Advanced Solid Tumor, Metastatic Cancer	12/26	11/27
CANFOUR, NCT03267316 / 2017-001111-36: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Completed	1/2	167	Europe	CAN04, Cisplatin, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed	Cantargia AB	Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer	03/24	03/24
NCT05426330: Advanced Cancer Patients' and Their Primary Caregivers' Willingness to Communicate About Advance Care Planning (ACP)	Recruiting	N/A	600	Europe		Jules Bordet Institute, Fonds Gaston Ithier, Université Libre de Bruxelles, Association Jules Bordet	Advanced Cancer	10/23	10/24